Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Remedy Plan Therapeutics has raised $18.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2025.
Remedy Plan Therapeutics's investors include Alexandria Venture Investments, Schooner Capital.
Remedy Plan Therapeutics is headquartered in Gaithersburg, United States.
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Remedy Plan Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Remedy Plan Therapeutics — Funding & Investors." VCBacked, May 13, 2025, https://www.vcbacked.co/company/remedy-plan-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). Remedy Plan Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/remedy-plan-therapeutics
{{cite web |title=Remedy Plan Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/remedy-plan-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated